Company: CSTL
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001447362-25-000069
Chunk: 113

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-05-05
Form: 10-Q
Item: Item 8
Chunk 113
---
 and the non-deductibility of other permanent items. 

14. Segment and Related Information

The Company derives revenues through the delivery of test reports for our molecular diagnostic tests. All of our operations are located within the United States and our business is focused on the U.S. market. We have a single reportable segment consisting of a single operating segment.

20

Table of ContentsCASTLE BIOSCIENCES, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)(UNAUDITED)

The measures of segment profit and loss for of our single reportable segment were as follows (in thousands):Three Months EndedMarch 31,20252024Net revenues from external customers(1)$87,988 $72,974 Significant segment expenses:Personnel costs52,200 45,916 Organizational and business development costs14,229 11,000 Inventory usage4,731 4,787 Clinical studies and publication costs2,085 2,637 Professional services3,576 3,124 Other segment items37,015 8,044 Segment loss$(25,848)$(2,534)(1)For information on disaggregation of segment revenue by type and information about payor concentration, see Note 3.Other segment itemsOther segment items include all other operating expenses types to included IT service and software licensing costs, fixed and variable expenses incurred for leasing of facilities and equipment, depreciation and amortization, gain or losses on disposal of fixed assets in the routine course of business, fair value adjustment for trading securities, realized gains or losses on investment securities, administrative costs, expense for use of prepaids to include insurance premiums and warranties for lab equipment, public company costs (less audit fees), interest and other non-operating income, and income tax expense or benefits. Our CODM does not individually review budgets or results for these activities.Other amounts included in the measure of segment profit or loss were as follows (in thousands):Three Months EndedMarch 31,20252024Interest income$3,099 $2,996 Interest expense(17)(14)Depreciation and amortization29,764 3,340 Income tax (benefit) expense(423)45 Stock-based compensation expense11,179 12,675 Changes in fair value of trading securities(1,425)— Total assets for our reportable segment were located in the United States and were $501.7 million and $531.2 million as